# ACG CASE REPORTS JOURNAL



CASE REPORT | ESOPHAGUS

# Development of Achalasia in a Patient With Chronic Intestinal Pseudo-Obstruction

Joshua Kwon, MD<sup>1</sup>, Andree Koop, MD<sup>2</sup>, and Dawn Francis, MD, MHS<sup>2</sup>

### **ABSTRACT**

Development of concurrent achalasia and chronic intestinal pseudo-obstruction (CIPO) is rare, although esophageal dysmotility is common in patients with CIPO and may suggest worse clinical outcomes. We present a case of a 63-year-old man with a 15-year history of CIPO who developed postprandial regurgitation, vomiting, and dysphagia and was diagnosed with achalasia through radiographic and endoscopic findings. This is only the third case in the reported literature that involves both conditions. Rather than representing 2 separate disorders, CIPO and achalasia may instead represent neurogenic variants of 1 underlying condition affecting the myenteric plexus.

#### INTRODUCTION

Chronic intestinal pseudo-obstruction (CIPO) is a rare gastrointestinal motility disorder characterized by signs and symptoms of bowel obstruction in the absence of any lesions occluding the intestinal lumen. The disease may occur secondary to neuropathic or myopathic processes; however, the exact etiology is often unclear. Achalasia is also a rare motility disorder of the esophagus but is characterized by impaired relaxation of the lower esophageal sphincter (LES) and absence of esophageal peristalsis. The development of these 2 conditions is rare, with 2 previous case reports in the medical literature.

# CASE REPORT

A 63-year-old white man with a 15-year history of idiopathic CIPO presented for evaluation. His gastrointestinal history began 15 years earlier when he developed a cecal volvulus and underwent ileocecal resection. Postoperatively, he developed persistent abdominal pain with imaging concerning for bowel obstruction. He underwent 2 exploratory laparotomies, which showed no evidence of mechanical obstruction or transition point. Intestinal transit studies showed delayed gastric emptying, and small bowel transit, and follow-up computed tomography (CT) scans showed persistently severely dilated bowel loops. He was not taking opioid or anticholinergic medications. He had no history of type 2 diabetes, celiac disease, connective tissue disease, or other skeletal muscle disorders. A paraneoplastic antibody screen was negative.

Gastroduodenal manometry demonstrated an abnormal contractile pattern consistent with a neuropathic process, and he was diagnosed with CIPO. Consequently, despite trials of several motility agents, including metoclopramide, prucalopride, and pyridostigmine, he was dependent on total parental nutrition (TPN) for the last 10 years because of symptoms and poor oral intake. He had also been treated with rotating antibiotics for small intestinal bacterial overgrowth and omeprazole for gastroesophageal reflux disease. He was initially treated with omeprazole 40 mg twice daily for 12 weeks and subsequently decreased to 20 mg daily with symptom improvement.

During a follow-up visit, the patient described new symptoms of postprandial nausea with vomiting, food regurgitation, and solid food dysphagia. An abdominal CT scan showed dilation of the distal thoracic esophagus and retention of oral contrast with narrowing of the gastroesophageal junction. Other findings included chronically dilated small bowel to the level of the terminal


ACG Case Rep J 2022;9:e00758. doi:10.14309/crj.000000000000758. Published online: June 3, 2022

Correspondence: Joshua Kwon, MD (kwon.joshua@mayo.edu).

<sup>&</sup>lt;sup>1</sup>Department of Medicine, Mayo Clinic, Jacksonville, FL

<sup>&</sup>lt;sup>2</sup>Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL

Kwon et al Development of Achalasia



**Figure 1.** Abdominal computed tomography with oral contrast. (A and B) Axial view demonstrates a dilated, fluid-filled esophagus at the level of gastroesophageal junction and evidence of chronically dilated bowel. (C and D) Coronal views of the dilated esophagus and dilated bowel are also provided. Red arrows outline the dilated esophagus in both views.

ileum, consistent with previous imaging and diagnosis of CIPO (Figure 1). A timed barium esophagram showed esophageal dilation with a bird beak appearance of the LES and a 5-cm fluid level of retained barium after 5 minutes (Figure 2). Esophagogastroduodenoscopy (EGD) showed a hypertonic LES with retention of saliva, mild esophagitis, absence of esophageal peristalsis, and resistance to endoscopic advancement into the stomach, concerning for achalasia (Figure 3). High-resolution esophageal manometry was attempted, but the study was prematurely aborted because of significant patient discomfort and inability to pass the catheter.

A repeat EGD was performed, which showed severe erosive esophagitis of the distal esophagus. Two mucosal tears were noted with the passage of the endoscope, so neither a manometry catheter (to later perform esophageal manometry) nor the endoluminal functional imaging probe was passed to limit further mucosal disruption. Based on clinical symptoms and findings seen on CT imaging, esophagram, and EGD, the patient was

diagnosed with achalasia and referred to surgery for myotomy. He was referred for a Heller myotomy based on local expertise and a lower suspicion for spastic type III achalasia, given the clinical history. Given CIPO and TPN dependence, it was felt that surgery would not improve his chances of tolerating a diet but rather reduce his symptoms of regurgitation, dysphagia, and risk of aspiration. A Heller myotomy with fundoplication was successfully performed with no major complications. One month after the procedure, the patient was seen in the clinic where he reported improved nausea and dysphagia.

## DISCUSSION

This is a case presentation of a patient with a long-standing history of CIPO and a new diagnosis of achalasia, the third described case of these 2 diagnoses in the medical literature.<sup>5,6</sup> Both previous cases describe patients who first developed achalasia and then developed CIPO several years later. Here, we describe the first case of a patient with long-standing CIPO and

Kwon et al Development of Achalasia



**Figure 2.** Timed barium esophagram with retained contrast at the distal esophageal junction and classic "bird beak narrowing" consistent with achalasia.

subsequent diagnosis of achalasia. CIPO does not represent a single disease entity but rather encompasses a group of disorders, resulting in failure of gut motility. Familial forms of CIPO have been reported, but most cases are believed to be sporadic.<sup>2</sup> Although CIPO may be secondary to known pathological conditions, the etiology is often idiopathic. Examples of secondary causes include paraneoplastic syndromes, radiation, connective tissue disorders (ie, Ehlers-Danlos syndrome), endocrinopathies (ie, hypothyroidism), autoimmune disease (ie, celiac disease), medication-induced (opioids), or infection (ie, Chagas disease). With a full-thickness biopsy, CIPO can be classified into 3 categories depending on the histopathological abnormality: myopathy (smooth muscle cells), mesenchymyopathy (interstitial cells of Cajal), and neuropathy (enteric nervous system).3 The cause of CIPO in this case presentation was believed to be neuropathic.

Although CIPO and achalasia describe separate disease entities, they may represent manifestations of the same underlying pathologic process. In achalasia, failure of the LES to relax is hypothesized secondary to loss of inhibitory innervation of the esophageal myenteric plexus. Similarly, CIPO may occur secondary to a neuropathic process affecting the myenteric plexus, and thus, these disorders may represent neurogenic variants of 1 underlying condition. Furthermore, in a previous study of patients with gastrointestinal motility disorders, antiganglionic acetylcholine receptor antibodies were found in 21.4% of patients with achalasia and 50% of patients with CIPO. This suggests that antiganglionic acetylcholine receptor antibodies may mediate autonomic dysfunction and contribute to an immune-mediated mechanism underlying these 2 diseases.



**Figure 3.** Esophagogastroduodenoscopy of the distal esophagus with evidence of narrowing at the lower esophageal sphincter, along with some evidence of esophagitis.

Although reports of overt achalasia and CIPO are rare, esophageal involvement with dysmotility is common in CIPO. In a retrospective study of 71 patients with CIPO who underwent esophageal manometry, 73% had abnormal motility patterns, including 68% with ineffective esophageal motility and 5% (4 patients) with vigorous achalasia. The 4 patients with achalasia were not further described. Esophageal motor disorders were associated with reduced survival, TPN requirement, and inability to maintain sufficient oral feeding.<sup>10</sup> Data remain limited on outcomes in patients with achalasia and CIPO. In conclusion, we describe a case presentation of a patient with CIPO who developed new esophageal symptoms and was subsequently diagnosed with achalasia. These 2 diseases may represent different manifestations of 1 underlying pathologic process. More research is required regarding the pathophysiological connection between achalasia and CIPO and the clinical outcomes in these patients.

### **DISCLOSURES**

Author contributions: J. Kwon wrote the manuscript and revised the manuscript for intellectual content. A. Koop and D. Francis revised the manuscript for intellectual content. D. Francis is the article guarantor.

Financial disclosure: None to report.

Informed consent was obtained for this case report.

Received July 6, 2021; Accepted November 17, 2021

# **REFERENCES**

- Stanghellini V, Camilleri M, Malagelada JR. Chronic idiopathic intestinal pseudo-obstruction: Clinical and intestinal manometric findings. Gut. 1987;28(1):5–12.
- Di Nardo G, Di Lorenzo C, Lauro A, et al. Chronic intestinal pseudoobstruction in children and adults: Diagnosis and therapeutic options. Neurogastroenterol Motil. 2017;29(1):e12945.

Kwon et al Development of Achalasia

- 3. De Giorgio R, Sarnelli G, Corinaldesi R, Stanghellini V. Advances in our understanding of the pathology of chronic intestinal pseudo-obstruction. *Gut.* 2004;53(11):1549–52.
- Boeckxstaens GE, Zaninotto G, Richter JE. Achalasia. Lancet. 2014; 383(9911):83–93.
- Sato H, Abe H, Nagashima A, Yokoyama J, Terai S. Gastrointestinal: A rare case of concomitant type III achalasia and chronic idiopathic intestinal pseudo-obstruction. J Gastroenterol Hepatol. 2018;33(3):559.
- Ang D, Teo EK, Ang TL, et al. Unexplained small-bowel obstruction in a patient with presumptive achalasia: Need for early recognition of chronic intestinal pseudo-obstruction (CIPO). *Dig Dis Sci.* 2010;55(9):2691–2.
  Downes TJ, Cheruvu MS, Karunaratne TB, De Giorgio R, Farmer AD.
- Downes TJ, Cheruvu MS, Karunaratne TB, De Giorgio R, Farmer AD. Pathophysiology, diagnosis, and management of chronic intestinal pseudoobstruction. J Clin Gastroenterol. 2018;52(6):477–89.
- 8. Park W, Vaezi MF. Etiology and pathogenesis of achalasia: The current understanding. *Am J Gastroenterol*. 2005;100(6):1404–14.

- Mukaino A, Minami H, Isomoto H, et al. Anti-ganglionic AChR antibodies in Japanese patients with motility disorders. *J Gastroenterol.* 2018;53(12): 1227–40.
- Amiot A, Joly F, Cazals-Hatem D, et al. Prognostic yield of esophageal manometry in chronic intestinal pseudo-obstruction: A retrospective cohort of 116 adult patients. *Neurogastroenterol Motil.* 2012;24(11):1008. e542.

Copyright: © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.